Clinical Trials Logo

Pneumonia clinical trials

View clinical trials related to Pneumonia.

Filter by:

NCT ID: NCT04263402 Recruiting - Clinical trials for 2019-nCoV Severe Pneumonia

The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia

Start date: February 1, 2020
Phase: Phase 4
Study type: Interventional

At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of different hormone doses in the treatment of 2019-nCoV severe Pneumonia.This study explores effective treatment programs for 2019-nCoV severe pneumonia and provides a reliable evidence-based basis for the treatment.

NCT ID: NCT04261270 Recruiting - 2019-nCoV Pneumonia Clinical Trials

A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia

Start date: February 1, 2020
Phase: Phase 3
Study type: Interventional

Based on oseltamivir treatment, evaluate the efficacy and safety of ASC09/ritonavir compound tablets(ASC09F) or ritonavir tablets for 2019-nCoV infection patients.

NCT ID: NCT04260308 Recruiting - Virus; Pneumonia Clinical Trials

A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia

Start date: February 3, 2020
Phase:
Study type: Observational

Due to the outbreak of 2019 Novel Coronavirus Pneumonia in Wuhan, Hubei province, medical staff and residents are facing great psychological pressure, the investigator plan to use electronic questionnaire to carry out investigation research.

NCT ID: NCT04256798 Recruiting - Anesthesia Clinical Trials

Perioperative Respiratory Care and Outcomes for Patients Undergoing High Risk Abdominal Surgery

PENGUIN
Start date: November 13, 2020
Phase: Phase 3
Study type: Interventional

PENGUIN is a pragmatic multi-center trial investigating the effects of pre-operative mouthwash and perioperative oxygen on the incidences of pneumonia and surgical site infection (SSI) following major abdominal surgery. Patients will be recruited from low and middle income countries and randomly assigned to a trial treatment arms: a) pre-operative chlorhexidine mouthwash and 80-100% FiO2; b) no pre-operative mouthwash and 80-100% fraction of inspired oxygen (FiO2); c) pre-operative chlorhexidine mouthwash and 21- 30% FiO2; or d) no pre-operative mouthwash and 21-30% FiO2.

NCT ID: NCT04255017 Recruiting - 2019-nCoV Clinical Trials

A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia

Start date: February 1, 2020
Phase: Phase 4
Study type: Interventional

At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of three antiviral drugs in the treatment of 2019-nCoV pneumonia by studying the efficacy of abidol hydrochloride, oseltamivir and lopinavir/ritonavir in the treatment of 2019-nCoV viral pneumonia, and to explore effective antiviral drugs for new coronavirus. To provide reliable evidence-based medicine basis for the treatment of viral pneumonia caused by new coronavirus infection.

NCT ID: NCT04254874 Recruiting - 2019-nCoV Clinical Trials

A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia

Start date: February 1, 2020
Phase: Phase 4
Study type: Interventional

At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of two therapeutic schemes(abidol hydrochloride,abidol hydrochloride combined with interferon atomization)in the treatment of 2019-nCoV viral pneumonia, so as to provide reliable evidence-based medicine for the treatment of viral pneumonia caused by 2019-nCoV.

NCT ID: NCT04252274 Recruiting - Coronavirus Clinical Trials

Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19

DC-COVID-19
Start date: January 30, 2020
Phase: Phase 3
Study type: Interventional

The study aims to evaluate the efficacy and safety of darunavir and cobistastat in the treatment of COVID-19 pneumonia

NCT ID: NCT04252118 Recruiting - COVID-19 Clinical Trials

Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19

Start date: January 27, 2020
Phase: Phase 1
Study type: Interventional

The SARS-CoV-2 infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. There is no confirmed antivirus therapy for people infected SARS-CoV-2, most of them should receive supportive care to help relieve symptoms. For severe cases, treatment should include care to support vital organ functions. This clinical trial is to inspect the safety and efficiency of Mesenchymal Stem Cells (MSCs) therapy for pneumonia patients infected with SARS-CoV-2.

NCT ID: NCT04251871 Recruiting - Clinical trials for Pneumonia Caused by Human Coronavirus (Disorder)

Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection

Start date: January 22, 2020
Phase: N/A
Study type: Interventional

The aim of this study is to test whether Traditional Chinese Medicines (TCMs) are effective and safe for treating COVID-19 infection. After the enrolment of approximately 30 subjects, the recruitment will be paused, and planned interim analysis will be performed to preliminarily investigate the efficacy and safety of TCMs in patients infected with COVID-19.

NCT ID: NCT04249050 Recruiting - Pneumonia Clinical Trials

Effects of Immunonutrition in Patients With Pneumonia

Start date: March 30, 2020
Phase: N/A
Study type: Interventional

The project is a randomized controlled trial taking place in the North Zealand hospital in the city Hilleroed, Denmark. The aim is to investigate the potential beneficial effects of immunonutrition containing fish oil, arginine and RNA, on the acute immune response in patients with pneumonia.